Ghost Tree Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Ghost Tree Capital’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-115,000	Closed	-$13.8M	–	67
2017 Q4	$13.8M	Buy	115,000 +15,000	+15%	+$1.83M	3.23%	7
2017 Q3	$14M	Hold	100,000	–	–	2.98%	8
2017 Q2	$12.2M	Buy	+100,000	New	+$11.6M	2.53%	12
2017 Q1	–	Sell	-115,000	Closed	-$14.1M	–	89
2016 Q4	$14.1M	Sell	115,000 -5,000	-4%	-$612K	3.39%	4
2016 Q3	$14.7M	Buy	120,000 +30,000	+33%	+$3.86M	2.38%	9
2016 Q2	$10.5M	Buy	90,000 +50,000	+125%	+$7.09M	3.03%	6
2016 Q1	$5.57M	Buy	+40,000	New	+$5.87M	3.15%	11
2015 Q3	–	Sell	-50,000	Closed	-$9.04M	–	104
2015 Q2	$9.04M	Buy	+50,000	New	+$8.63M	2.93%	10

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ghost Tree Capital's ALXN Position: Q1 2018 in Review

Ghost Tree Capital sold out of Alexion Pharmaceuticals (ALXN) in Q1 2018, closing a stake of 115,000 shares — an estimated $13.8M sold.

Ghost Tree Capital first reported a position in ALXN in Q2 2015 and held it in 8 quarters. The position peaked at $14.7M in Q3 2016. 596 funds tracked by Wall St. Rank hold ALXN as of Q1 2018.

Ghost Tree Capital reported no remaining Alexion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Ghost Tree Capital sold 115,000 Alexion Pharmaceuticals shares in Q1 2018, an estimated $13.8M.
Ghost Tree Capital first reported a position in Alexion Pharmaceuticals in Q2 2015 and held it in 8 quarters.
Ghost Tree Capital's Alexion Pharmaceuticals position peaked at $14.7M in Q3 2016.
596 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2018.

Based on Ghost Tree Capital's 13F filing for Q1 2018, filed 15 May 2018.